Literature DB >> 9148658

Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians.

D F Ransohoff1, C A Lang.   

Abstract

PURPOSE: Screening for colorectal cancer with fecal occult blood tests or sigmoidoscopy can reduce mortality rates. If occult blood testing is done, clinicians must decide how to interpret the results and plan further management. If the results are positive, a decision must be made about evaluating the colon. This report provides information that can be used to perform fecal occult blood tests, interpret the results of those tests, and plan patient management. DATA SOURCES: The MEDLINE database was searched for data relevant to optimizing the technique of fecal occult blood testing. Studies were also identified from the bibliographies of published articles about test performance and the interpretation of test results, particularly sensitivity, specificity, and the probability of colorectal cancer after a positive test result. STUDY SELECTION AND DATA EXTRACTION: Studies were selected and data were extracted on the basis of the authors' combined judgment. DATA SYNTHESIS: When used for screening, fecal occult blood tests have positive results about 1% to 16% of the time, depending on such factors as the age of the person being tested, whether the sample is rehydrated, and whether the test is used for initial screening or for rescreening. When the colons of persons who have positive test results are evaluated, the rate of finding any colorectal cancer is about 2% to 17% and the rate for early colorectal cancer (Dukes stage A or B) is about 2% to 14%.
CONCLUSIONS: These results suggest that, in general, persons who have positive results on a fecal occult blood test should have a full colonic examination. More research is needed to understand and improve the sensitivity and specificity of the fecal occult blood test.

Entities:  

Mesh:

Year:  1997        PMID: 9148658     DOI: 10.7326/0003-4819-126-10-199705150-00014

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  27 in total

1.  Prevention of Colorectal Cancer.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-02

2.  [Conventional and molecular screening (fecal tests)].

Authors:  C Pox; K Schulmann; W Schmiegel
Journal:  Internist (Berl)       Date:  2003-03       Impact factor: 0.743

Review 3.  Effect of verification bias on the sensitivity of fecal occult blood testing: a meta-analysis.

Authors:  Alan S Rosman; Mark A Korsten
Journal:  J Gen Intern Med       Date:  2010-05-25       Impact factor: 5.128

4.  Screening for colon cancer.

Authors:  J P Heiken
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

Review 5.  Cancer screening in renal transplant recipients: what is the evidence?

Authors:  Germaine Wong; Jeremy R Chapman; Jonathan C Craig
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

Review 6.  Colorectal cancer screening.

Authors:  R Scott Nelson; Alan G Thorson
Journal:  Curr Oncol Rep       Date:  2009-11       Impact factor: 5.075

Review 7.  2017 Emily Couric Memorial Lecture: Colorectal Cancer: Polyps, Prevention, and Progress.

Authors:  Mark B Pochapin
Journal:  Am J Gastroenterol       Date:  2018-12       Impact factor: 10.864

Review 8.  Screening for cancer: valuable or not?

Authors:  Frank L Meyskens
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

Review 9.  Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears.

Authors:  M E de Noo; R A E M Tollenaar; A M Deelder; L H Bouwman
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

10.  Preoperative evaluation and oncologic principles of colon cancer surgery.

Authors:  Matthew L Lynch; Marc I Brand
Journal:  Clin Colon Rectal Surg       Date:  2005-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.